Hoffmann-La Roche

WO42017 | Skyscraper 04

NCT04300647

JCP083

A Study of Tiragolumab Plus Atezolizumab and Atezolizumab Monotherapy in Participants With Metastatic and/or Recurrent PD-L1-Positive Cervical Cancer (SKYSCRAPER-04)

Status:

Closed to Accrual

26459-200.png

II

Phase

Line of Therapy.png

1st+

Line of Therapy

Disease Stage.png

Advanced / Metastatic

Disease Stage

Target.png

Biomarker(s)

PD-L1

Investigational

Product

Tiragolumab

Anti-TIGIT monoclonal antibody (i.v.)

Treatment Arms

o Experimental: Tiragolumab plus Atezolizumab

o Experimental: Atezolizumab